

CPE Activity Information

E-LEARNING

Suspect and Illegitimate Product Under the DSCSA



Available September 21, 2026 – September 20, 2029

Self-paced e-learning · 1.5 contact hours

Activity Overview

The Drug Supply Chain Security Act (DSCSA) requires trading partners to identify, quarantine, investigate, and notify when they encounter suspect or illegitimate product. Failure to recognize the warning signs of counterfeit, diverted, or stolen drugs can allow dangerous products to reach patients.

This course walks participants through FDA's definitions of suspect and illegitimate product, the red flags that signal a product may require further scrutiny, and the identification and quarantine steps trading partners must take under the DSCSA. A real-world case study — the investigation of counterfeit Ozempic® pens distributed outside the authorized supply chain — illustrates how these concepts apply in practice.

Activity Topic	Law (Regulatory Compliance)
Activity Format	Self-Paced E-Learning
Universal Activity Numbers	0205-9999-26-104-H03-P 0205-9999-26-104-H03-T
Course Provider	NABP / Ten Count Consulting LLC
Platform	dscsa.learningcart.com
Activity Date	9/21/2026 – 9/20/2029
Activity Type	Knowledge-based

Credit	1.5 contact hours (0.15 CEU)
---------------	------------------------------

Activity Fee	\$195
---------------------	-------

Target Audience

This activity was designed to meet the educational needs of pharmacists, pharmacy technicians, wholesale distributors, and other trading partners with responsibilities under the DSCSA.

Learning Objectives

At the conclusion of this course, participants will be able to:

- Describe the four key systems (processes) trading partners are required to have in place regarding suspect and illegitimate product.
- Explain DSCSA and FDA guidance definitions for suspect and illegitimate product.
- Describe when and why a product must be treated as suspect or illegitimate.
- Recognize common red flags of a suspect product.

CPE Requirements

To earn credit for this activity, participants must:

- Complete the course in its entirety.
- Review all course content, case study materials, and reference material handouts.
- Pass the knowledge check with a score of 80% or higher.
- Complete the course evaluation form.

To obtain CPE credit, participants must complete the course evaluation after the course. The course evaluation will gather NABP e-PID number, month/day of birth, and professional designation (Pharmacist or Pharmacist Technician) for submission to CPE Monitor®.

All CPE submissions may take 10–14 days to be reflected in CPE Monitor®.

Course Content Summary

Why This Matters	The DSCSA's goal is to prevent, detect, and respond to dangerous drugs entering the supply chain.
Verification Systems	Identify, Quarantine, Investigate, Notify
Key Definitions	Suspect (reason to believe) vs. Illegitimate (credible evidence)
Product Categories	Counterfeit, diverted, stolen, fraudulent transaction, unfit for distribution (adulterated/misbranded)
Identification Indicators	Trading partner/sourcing red flags, supply/demand/history/value red flags, product appearance red flags
Case Study	Investigation of counterfeit Ozempic pen

Additional Course Information

Contact info@tencountconsulting.com for information about this course or technical assistance.

Additional CPE Information

Contact NABP staff at CPE@nabp.pharmacy for information about claiming CPE credit.



NABP and the NABP Foundation are accredited by the ACPE as providers of continuing pharmacy education (CPE).

ACPE Provider Number: 0205.

System Requirements

Internet connection: Stable broadband connection (course content includes video and interactive elements)

Web browser: Current version of Google Chrome, Microsoft Edge, Mozilla Firefox, or Safari (updated within the last 2 major versions)

Device: Desktop, laptop, tablet, or smartphone

Screen resolution: Minimum 1024 x 768 recommended for optimal viewing

PDF reader: Required to view/print supplemental materials and certificates

Speakers/headphones: Course includes audio or video narration

Account/login: Active LearningCart account with course access granted through dscsa.learningcart.com

Read more about [Ten Count Consulting's policy on privacy and confidentiality](#).

Read more about [NABP's policy on privacy and confidentiality](#).

Financial Disclosures

Ten Count Consulting, LLC, declares that it has a current affiliation or financial arrangement with ineligible companies as a consultant for multiple pharmaceutical manufacturers and distributors. All relevant financial relationships have been mitigated.

© 2026 Ten Count Consulting. All rights reserved. This material may not be reproduced, shared, or distributed without prior written permission.